GB0208609D0 - Compositions - Google Patents

Compositions

Info

Publication number
GB0208609D0
GB0208609D0 GBGB0208609.8A GB0208609A GB0208609D0 GB 0208609 D0 GB0208609 D0 GB 0208609D0 GB 0208609 A GB0208609 A GB 0208609A GB 0208609 D0 GB0208609 D0 GB 0208609D0
Authority
GB
United Kingdom
Prior art keywords
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0208609.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0208609.8A priority Critical patent/GB0208609D0/en
Publication of GB0208609D0 publication Critical patent/GB0208609D0/en
Priority to MXPA04010082A priority patent/MXPA04010082A/es
Priority to PCT/GB2003/001595 priority patent/WO2003088944A1/en
Priority to US10/510,968 priority patent/US20050232998A1/en
Priority to PL03373293A priority patent/PL373293A1/xx
Priority to EP03720702A priority patent/EP1509199A1/en
Priority to RU2004130438/15A priority patent/RU2004130438A/ru
Priority to KR10-2004-7016301A priority patent/KR20040097348A/ko
Priority to BR0309115-5A priority patent/BR0309115A/pt
Priority to JP2003585696A priority patent/JP2005529874A/ja
Priority to CNB038134608A priority patent/CN100362986C/zh
Priority to CA002482249A priority patent/CA2482249A1/en
Priority to AU2003224278A priority patent/AU2003224278A1/en
Priority to TW092108404A priority patent/TW200407174A/zh
Priority to ARP030101279A priority patent/AR039408A1/es
Priority to IL16442104A priority patent/IL164421A0/xx
Priority to IS7501A priority patent/IS7501A/is
Priority to ZA200408247A priority patent/ZA200408247B/xx
Priority to NO20044496A priority patent/NO20044496L/no
Priority to US11/934,983 priority patent/US20080060645A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0208609.8A 2002-04-13 2002-04-13 Compositions Ceased GB0208609D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB0208609.8A GB0208609D0 (en) 2002-04-13 2002-04-13 Compositions
AU2003224278A AU2003224278A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition
BR0309115-5A BR0309115A (pt) 2002-04-13 2003-04-10 Composição farmacêutica em pó seco, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, embalagem de medicamento, e, uso de carboidratos derivados particulados em composição farmacêutica em pó seco
CNB038134608A CN100362986C (zh) 2002-04-13 2003-04-10 干粉吸入组合物
US10/510,968 US20050232998A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition
PL03373293A PL373293A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition
EP03720702A EP1509199A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition
RU2004130438/15A RU2004130438A (ru) 2002-04-13 2003-04-10 Сухая порошковая композиция для ингаляции
KR10-2004-7016301A KR20040097348A (ko) 2002-04-13 2003-04-10 흡입용 건조 분말 조성물
MXPA04010082A MXPA04010082A (es) 2002-04-13 2003-04-10 Composicion inhalante de polvo seco.
JP2003585696A JP2005529874A (ja) 2002-04-13 2003-04-10 乾燥粉末組成物
PCT/GB2003/001595 WO2003088944A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition
CA002482249A CA2482249A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition
ARP030101279A AR039408A1 (es) 2002-04-13 2003-04-11 Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento
TW092108404A TW200407174A (en) 2002-04-13 2003-04-11 Composition
IL16442104A IL164421A0 (en) 2002-04-13 2004-10-05 Dry powder inhalant composition
IS7501A IS7501A (is) 2002-04-13 2004-10-11 thurrdufts innöndunar samsetning
ZA200408247A ZA200408247B (en) 2002-04-13 2004-10-12 Dry powder inhalant composition
NO20044496A NO20044496L (no) 2002-04-13 2004-10-21 Torr pulver innhaleringssammensetning
US11/934,983 US20080060645A1 (en) 2002-04-13 2007-11-05 Dry Powder Inhalant Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0208609.8A GB0208609D0 (en) 2002-04-13 2002-04-13 Compositions

Publications (1)

Publication Number Publication Date
GB0208609D0 true GB0208609D0 (en) 2002-05-22

Family

ID=9934856

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0208609.8A Ceased GB0208609D0 (en) 2002-04-13 2002-04-13 Compositions

Country Status (19)

Country Link
US (2) US20050232998A1 (https=)
EP (1) EP1509199A1 (https=)
JP (1) JP2005529874A (https=)
KR (1) KR20040097348A (https=)
CN (1) CN100362986C (https=)
AR (1) AR039408A1 (https=)
AU (1) AU2003224278A1 (https=)
BR (1) BR0309115A (https=)
CA (1) CA2482249A1 (https=)
GB (1) GB0208609D0 (https=)
IL (1) IL164421A0 (https=)
IS (1) IS7501A (https=)
MX (1) MXPA04010082A (https=)
NO (1) NO20044496L (https=)
PL (1) PL373293A1 (https=)
RU (1) RU2004130438A (https=)
TW (1) TW200407174A (https=)
WO (1) WO2003088944A1 (https=)
ZA (1) ZA200408247B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
EP1643974A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Inhalable pharmaceutical formulations comprising a sugar ester
MX2007009656A (es) 2005-02-10 2007-11-07 Glaxo Group Ltd Proceso para elaborar lactosa utilizando tecnicas de clasificacion previa y formulaciones farmaceuticas formadas de la misma.
GB0605723D0 (en) 2006-03-23 2006-05-03 3M Innovative Properties Co Powder filling processes
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
BRPI0816278A2 (pt) * 2007-09-05 2015-09-22 Pfizer Ltd forma sal
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
TR201007251A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Kalsiyum kanal blokörü formülasyonu.
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
NZ629438A (en) * 2012-02-28 2016-10-28 Iceutica Holdings Inc Inhalable pharmaceutical compositions
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2847207B1 (en) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Fluticasone propionate nanocrystals
EP2874928B1 (en) 2012-07-19 2016-06-15 Adamis Pharmaceuticals Corporation Powder feeding apparatus
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
AU2014261538A1 (en) * 2013-04-29 2015-12-10 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them
CN104644618A (zh) * 2013-11-19 2015-05-27 上海医药工业研究院 一种干粉吸入剂及其制备方法
EP4218734A1 (en) * 2014-07-31 2023-08-02 Vectura Inc. Dry powder formulations for inhalation
WO2016052897A1 (en) * 2014-09-30 2016-04-07 Hanmi Pharm. Co., Ltd. Dry powder for inhalation formulation having improved stability of combined active ingredients
KR20160117069A (ko) * 2015-03-31 2016-10-10 한미약품 주식회사 복합 활성성분의 안정성이 개선된 흡입용 캡슐제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) * 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
AU591152B2 (en) * 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
PT994887E (pt) * 1997-07-03 2003-04-30 Elan Drug Delivery Ltd Glicosidos modificados composicoes que compreendem os mesmos e metodos para a sua utilizacao
US6352722B1 (en) * 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
JP2004526674A (ja) * 2000-12-01 2004-09-02 バテル・メモリアル・インスティテュート 液体処方物中における生体分子の安定化のための方法
PT1372608E (pt) * 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
WO2003099764A1 (en) * 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS

Also Published As

Publication number Publication date
CN1658837A (zh) 2005-08-24
AR039408A1 (es) 2005-02-16
US20050232998A1 (en) 2005-10-20
MXPA04010082A (es) 2004-12-13
PL373293A1 (en) 2005-08-22
US20080060645A1 (en) 2008-03-13
IS7501A (is) 2004-10-11
IL164421A0 (en) 2005-12-18
NO20044496L (no) 2004-11-15
TW200407174A (en) 2004-05-16
AU2003224278A1 (en) 2003-11-03
KR20040097348A (ko) 2004-11-17
BR0309115A (pt) 2005-02-01
JP2005529874A (ja) 2005-10-06
WO2003088944A1 (en) 2003-10-30
CN100362986C (zh) 2008-01-23
CA2482249A1 (en) 2003-10-30
RU2004130438A (ru) 2005-06-10
ZA200408247B (en) 2006-03-29
EP1509199A1 (en) 2005-03-02

Similar Documents

Publication Publication Date Title
GB0212062D0 (en) Jetable compositions
IL165372A0 (en) Immunodenic compositions
GB0224415D0 (en) Compositions
GB0220467D0 (en) Composition
GB0213638D0 (en) Composition
GB0318894D0 (en) Composition
GB0208609D0 (en) Compositions
GB0203421D0 (en) Composition
GB0227244D0 (en) Composition
GB0208608D0 (en) Composition
GB0221894D0 (en) Compositions
GB0203280D0 (en) Anti-glycolytic composition
AU2003269904A8 (en) Antigen-polymer compositions
GB0203395D0 (en) Compositions
GB0203396D0 (en) Compositions
GB0211924D0 (en) Composition
GB0229808D0 (en) Novel compositions
GB0230274D0 (en) Composition
GB0218241D0 (en) Composition
GB0217366D0 (en) Compositions
EP1495751A4 (en) hair dye
GB2394114B (en) Compositions
AU2003216382A8 (en) Idothyronine compositions
GB0228540D0 (en) Novel compositions
GB0229286D0 (en) Composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)